Study Explores Use of Checkpoint Inhibitors After Relapse From Donor Stem Cell Transplant for Hematologic Cancers
December 09, 2017
December 09, 2017
BOSTON, Massachusetts, Dec. 9 -- The Dana-Farber Cancer Institute issued the following news release:
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent -- nivolumab -- indicate that along with signs of effectiveness, it also produced significant side effects at the dose initia . . .
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent -- nivolumab -- indicate that along with signs of effectiveness, it also produced significant side effects at the dose initia . . .